Oncogenesis (Jan 2021)

PBK phosphorylates MSL1 to elicit epigenetic modulation of CD276 in nasopharyngeal carcinoma

  • Meng-Yao Wang,
  • Bin Qi,
  • Fang Wang,
  • Zhi-Rui Lin,
  • Ming-Yi Li,
  • Wen-Jing Yin,
  • Yan-Yi Zhu,
  • Lu He,
  • Yi Yu,
  • Fang Yang,
  • Jin-Quan Liu,
  • Dong-Ping Chen

DOI
https://doi.org/10.1038/s41389-020-00293-9
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 14

Abstract

Read online

Abstract CD276 (also known as B7–H3, an immune checkpoint molecule) is aberrantly overexpressed in many cancers. However, the upregulation mechanism and in particular, whether oncogenic signaling has a role, is unclear. Here we demonstrate that a pro-oncogenic kinase PBK, the expression of which is associated with immune infiltration in nasopharyngeal carcinoma (NPC), stimulates the expression of CD276 epigenetically. Mechanistically, PBK phosphorylates MSL1 and enhances the interaction between MSL1 and MSL2, MSL3, and KAT8, the components of the MSL complex. As a consequence, PBK promotes the enrichment of MSL complex on CD276 promoter, leading to the increased histone H4 K16 acetylation and the activation of CD276 transcription. In addition, we show that CD276 is highly upregulated and associated with immune infiltrating levels in NPC. Collectively, our findings describe a novel PBK/MSL1/CD276 signaling axis, which may play an important role in immune evasion of NPC and may be targeted for cancer immunotherapy.